Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMYD2 | Q9NRG4 | 2/20 | 0.33 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.33 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.33 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.31 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24312400 | 0.90 | CYP2D6 (0.38) | CYP2D6CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL7155286 | 0.89 | CYP2D6 (0.37) | CYP2D6CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL21873649 | 0.87 | CYP1A2 (0.42) | CYP2D6CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL2531862 | 0.87 | CYP1A2 (0.42) | CYP2D6CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL218117 | 0.87 | CYP1A2 (0.42) | CYP2D6CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL6158503 | 0.86 | CYP3A4 (0.37) | CYP2D6CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL6156817 | 0.84 | AR (0.41) | CYP2D6CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL15209484 | 0.84 | ALOX15 (0.44) | CYP2D6CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL15209482 | 0.84 | ALOX15 (0.44) | CYP2D6CYP3A4HTTSMN1; SMN2KMT2A | |
| SCHEMBL31200933 | 0.84 | MAPT (0.44) | CYP2D6CYP3A4HTTSMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067459-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067459-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-8067459-B2 | Lapachone compounds and methods of use thereof | ARQULE, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20090176801-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176801-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176801-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | ARQULE, INC. (US) | 2009-07-09 | — | — | US | disclosed |
| US-6194576-B1 | COUPLING PURINE OR PYRIMIDINE BASE WITH NUCLEOTIDE ANALOG PHOSPHONATE COMPOUND | BIOCHEM PHARMA, INC. (CA) | 2001-02-27 | — | — | US | disclosed |
| US-6127540-A | NUCLEOTIDE ANALOGS MADE BY COUPLING A PURINE OR PYRIMIDINE NUCLEOTIDE BASE OR ANALOGUE THEREOF WITH A 2-(PHOSPHONATE)FURAN OR 2-(PHOSPHONATE)THIOFURAN OF GIVEN FORMULA; USE AS NON-TOXIC ANTIVIRAL DRUGS | BIOCHEM PHARMA, INC. (CA) | 2000-10-03 | — | — | US | disclosed |
| US-6005107-A | Antiviral compounds | BIOCHEM PHARMA, INC. (CA) | 1999-12-21 | — | — | US | disclosed |
| US-5955610-A | COUPLING PHOSPHONATE INTERMEDIATE WITH PURINE OR PYRIMIDINE NUCLEOTIDE BASE | BIOCHEM PHARMA, INC. (CA) | 1999-09-21 | — | — | US | disclosed |
| US-5789394-A | VIRICIDES FOR CYTOMEGALOVIRUS USING NUCLEOTIDES | NGUYEN-BA NGHE (CA) | 1998-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090176801-A1 | NOVEL LAPACHONE COMPOUNDS AND METHODS OF USE THEREOF | MKI67, NQO1, XIAP | CYP2D6 1690/4885CYP3A4 1600/4885HTT 2192/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.